Companies › SABS
SAB BIOTHERAPEUTICS INC (SABS)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001833214 · EDGAR filings · Updated 2026-07-07
SAB BIOTHERAPEUTICS INC (SABS) has reported institutional ownership of 135.8%, with 76 institutional managers holding positions valued at $265.0M per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-07-07 — Current report (8-K) filed
- 2026-06-26 — Insider transaction reported (Form 4)
- 2026-06-18 — Current report (8-K) filed
- 2026-05-15 — SCHEDULE 13G/A filed
- 2026-05-15 — SCHEDULE 13G filed
- 2026-05-15 — SCHEDULE 13G filed
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, SAB BIOTHERAPEUTICS INC has 76 institutional holders and institutional ownership of 135.8%.
Insider activity
Insiders reported 6 transactions (0 buys, 0 sells) across 3 reporting insiders, with a net reported value of $0.
Data flags from SEC filings
Related companies
CERUS CORP (CERS) · CORMEDIX INC (CRMD) · STANDARD BIOTOOLS INC (LAB) · REZOLUTE INC (RZLT) · ORTHOPEDIATRICS CORP (KIDS) · SURROZEN INC (SRZN)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-07.